Recursion Pharmaceuticals (RXRX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

RXRX Stock Forecast

Recursion Pharmaceuticals stock forecast is as follows: an average price target of $9.67 (represents a 60.36% upside from RXRX’s last price of $6.03) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.

RXRX Price Target

The average price target for Recursion Pharmaceuticals (RXRX) is $9.67 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $6.00. This represents a potential 60.36% upside from RXRX's last price of $6.03.

RXRX Analyst Ratings

Hold

According to 5 Wall Street analysts, Recursion Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for RXRX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (20.00%), 4 'Hold' (80.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Recursion Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 04, 2024	Gil Blum	Needham	$11.00	$6.10	80.33%	82.42%
Sep 03, 2024	Scott Schoenhaus	KeyBanc	$12.00	$6.07	97.69%	99.00%
Sep 03, 2024	Dennis Ding	Jefferies	$6.00	$6.02	-0.34%	-0.50%
Jun 26, 2024	Scott Schoenhaus	KeyBanc	$16.00	$8.76	82.65%	165.34%

The latest Recursion Pharmaceuticals stock forecast, released on Sep 04, 2024 by Gil Blum from Needham, set a price target of $11.00, which represents a 80.33% increase from the stock price at the time of the forecast ($6.10), and a 82.42% increase from RXRX last price ($6.03).

Recursion Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	4
Avg Price Target	-	-	$11.25
Last Closing Price	$6.03	$6.03	$6.03
Upside/Downside	-100.00%	-100.00%	86.57%

In the current month, the average price target of Recursion Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Recursion Pharmaceuticals's last price of $6.03. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 04, 2024	Needham	Market Perform	Market Perform	Hold
Sep 04, 2024	Needham	Buy	Buy	Hold
Sep 03, 2024	KeyBanc	Overweight	Overweight	Hold
Sep 03, 2024	Cowen & Co.	Hold	Hold	Hold
Sep 03, 2024	Jefferies	Hold	Hold	Hold
Jun 26, 2024	KeyBanc	Overweight	Overweight	Hold
May 10, 2024	Needham	Buy	Buy	Hold
Apr 09, 2024	Needham	Buy	Buy	Hold
Mar 04, 2024	Needham	Buy	Buy	Hold
Jan 17, 2024	Needham	Buy	Buy	Hold
Apr 26, 2022	Zacks Investment Research		Hold	Upgrade

Recursion Pharmaceuticals's last stock rating was published by Needham on Sep 04, 2024. The company gave RXRX a "Market Perform" rating, the same as its previous rate.

Recursion Pharmaceuticals Financial Forecast

Recursion Pharmaceuticals Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$10.89M	$10.10M	$11.02M	$12.13M	$13.68M	$13.05M	$7.65M	$5.30M	$2.50M	$2.53M	$2.55M	$2.56M
Avg Forecast	$30.00M	$35.00M	$5.00M	$5.00M	$20.83M	$14.68M	$12.22M	$12.97M	$12.19M	$18.72M	$11.96M	$11.10M	$19.90M	$11.24M	$11.87M	$12.81M	$23.80M	$6.84M	$5.33M	$83.95M	$6.03M	$2.67M	$2.73M	$2.67M
High Forecast	$45.15M	$52.67M	$7.52M	$7.52M	$31.35M	$22.08M	$18.40M	$19.53M	$19.41M	$28.17M	$11.96M	$16.70M	$31.04M	$11.24M	$17.86M	$19.27M	$35.82M	$6.84M	$5.33M	$83.95M	$6.03M	$2.67M	$2.73M	$2.67M
Low Forecast	$16.15M	$18.84M	$2.69M	$2.69M	$11.22M	$7.90M	$6.58M	$6.99M	$3.00M	$10.08M	$11.96M	$5.98M	$7.75M	$11.24M	$6.39M	$6.90M	$12.81M	$6.84M	$5.33M	$83.95M	$6.03M	$2.67M	$2.73M	$2.67M
# Analysts	1	1	1	1	1	1	1	2	5	4	4	4	5	4	4	4	3	3	3	3	4	4	4	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.55%	0.90%	0.93%	0.95%	0.57%	1.91%	1.43%	0.06%	0.41%	0.95%	0.94%	0.96%

Recursion Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 4 analysts is $11.10M, with a low forecast of $5.98M, and a high forecast of $16.70M. RXRX's average Quarter revenue forecast represents a 1.92% increase compared to the company's last Quarter revenue of $10.89M (Dec 23).

Recursion Pharmaceuticals EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	1	1	1	1	1	1	1	2	5	4	4	4	5	4	4	4	3	3	3	3	4	4	4	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-98.93M	$-85.41M	$-81.72M	$-61.58M	$-60.98M	$-57.44M	$-62.76M	$-53.20M	$-62.70M	$-44.77M	$-38.57M	$-29.07M
Avg Forecast	$-30.00M	$-35.00M	$-5.00M	$-5.00M	$-20.83M	$-14.68M	$-12.22M	$-12.97M	$-12.19M	$-18.72M	$-11.96M	$-11.10M	$-19.90M	$-11.24M	$-11.87M	$-12.81M	$-23.80M	$-6.84M	$-5.33M	$-253.75M	$-6.03M	$-2.67M	$-25.15M	$-2.67M
High Forecast	$-16.15M	$-18.84M	$-2.69M	$-2.69M	$-11.22M	$-7.90M	$-6.58M	$-6.99M	$-3.00M	$-10.08M	$-11.96M	$-5.98M	$-7.75M	$-11.24M	$-6.39M	$-6.90M	$-12.81M	$-6.84M	$-5.33M	$-203.00M	$-6.03M	$-2.67M	$-20.12M	$-2.67M
Low Forecast	$-45.15M	$-52.67M	$-7.52M	$-7.52M	$-31.35M	$-22.08M	$-18.40M	$-19.53M	$-19.41M	$-28.17M	$-11.96M	$-16.70M	$-31.04M	$-11.24M	$-17.86M	$-19.27M	$-35.82M	$-6.84M	$-5.33M	$-304.51M	$-6.03M	$-2.67M	$-30.18M	$-2.67M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	4.97%	7.60%	6.89%	4.81%	2.56%	8.39%	11.77%	0.21%	10.39%	16.74%	1.53%	10.87%

undefined analysts predict RXRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Recursion Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Recursion Pharmaceuticals Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	1	1	1	1	1	1	1	2	5	4	4	4	5	4	4	4	3	3	3	3	4	4	4	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-93.00M	$-93.02M	$-76.73M	$-60.79M	$-57.48M	$-58.32M	$-65.55M	$-55.98M	$-64.95M	$-48.45M	$-45.87M	$-30.95M
Avg Forecast	$-81.95M	$-73.47M	$-101.73M	$-98.90M	$-127.16M	$-132.11M	$-137.05M	$-136.35M	$-115.05M	$-94.05M	$-108.59M	$-119.63M	$-126.81M	$-108.90M	$-105.97M	$-98.50M	$-81.95M	$-91.73M	$-90.42M	$-267.02M	$-74.27M	$-67.81M	$-28.30M	$-57.32M
High Forecast	$-32.77M	$-29.38M	$-40.69M	$-39.56M	$-50.86M	$-52.83M	$-54.81M	$-54.53M	$-95.33M	$-37.61M	$-43.43M	$-47.84M	$-82.70M	$-43.55M	$-42.38M	$-39.39M	$-32.77M	$-91.73M	$-90.42M	$-213.62M	$-74.27M	$-67.81M	$-22.64M	$-57.32M
Low Forecast	$-135.73M	$-121.69M	$-168.50M	$-163.82M	$-210.62M	$-218.81M	$-227.00M	$-225.83M	$-138.06M	$-155.78M	$-179.86M	$-198.14M	$-162.65M	$-180.38M	$-175.51M	$-163.14M	$-135.73M	$-91.73M	$-90.42M	$-320.42M	$-74.27M	$-67.81M	$-33.97M	$-57.32M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.73%	0.85%	0.72%	0.62%	0.70%	0.64%	0.72%	0.21%	0.87%	0.71%	1.62%	0.54%

Recursion Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RXRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Recursion Pharmaceuticals SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	1	1	1	1	1	1	1	2	5	4	4	4	5	4	4	4	3	3	3	3	4	4	4	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$30.46M	$29.20M	$28.29M	$22.87M	$19.84M	$19.49M	$21.20M	$21.07M	$19.20M	$15.69M	$13.85M	$8.94M
Avg Forecast	$172.72M	$201.51M	$28.79M	$28.79M	$119.95M	$84.49M	$70.38M	$74.70M	$70.16M	$107.76M	$68.84M	$63.91M	$114.55M	$64.70M	$68.32M	$73.74M	$137.03M	$39.40M	$30.71M	$483.34M	$34.74M	$15.40M	$15.69M	$15.40M
High Forecast	$259.92M	$303.24M	$43.32M	$43.32M	$180.50M	$127.15M	$105.92M	$112.42M	$111.78M	$162.17M	$68.84M	$96.17M	$178.72M	$64.71M	$102.81M	$110.97M	$206.21M	$39.40M	$30.71M	$483.34M	$34.74M	$15.40M	$15.69M	$15.40M
Low Forecast	$93.00M	$108.50M	$15.50M	$15.50M	$64.58M	$45.49M	$37.90M	$40.22M	$17.26M	$58.02M	$68.84M	$34.41M	$44.63M	$64.70M	$36.78M	$39.70M	$73.78M	$39.40M	$30.71M	$483.34M	$34.74M	$15.40M	$15.69M	$15.40M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.27%	0.45%	0.41%	0.31%	0.14%	0.49%	0.69%	0.04%	0.55%	1.02%	0.88%	0.58%

Recursion Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $63.91M, based on 4 Wall Street analysts, with a range of $34.41M to $96.17M. The forecast indicates a 109.82% rise compared to RXRX last annual SG&A of $30.46M (Dec 23).

Recursion Pharmaceuticals EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	1	1	1	1	1	1	1	2	5	4	4	4	5	4	4	4	3	3	3	3	4	4	4	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.40	$-0.43	$-0.38	$-0.32	$-0.31	$-0.34	$-0.38	$-0.33	$-0.38	$-0.29	$-0.33	$-0.20
Avg Forecast	$-0.29	$-0.26	$-0.36	$-0.35	$-0.45	$-0.47	$-0.48	$-0.48	$-0.41	$-0.33	$-0.38	$-0.42	$-0.45	$-0.39	$-0.37	$-0.35	$-0.29	$-0.38	$-0.37	$0.10	$-0.31	$-0.28	$-0.23	$-0.24
High Forecast	$-0.12	$-0.10	$-0.14	$-0.14	$-0.18	$-0.19	$-0.19	$-0.19	$-0.34	$-0.13	$-0.15	$-0.17	$-0.29	$-0.15	$-0.15	$-0.14	$-0.12	$-0.38	$-0.37	$0.10	$-0.31	$-0.28	$-0.23	$-0.24
Low Forecast	$-0.48	$-0.43	$-0.60	$-0.58	$-0.75	$-0.77	$-0.80	$-0.80	$-0.49	$-0.55	$-0.64	$-0.70	$-0.58	$-0.64	$-0.62	$-0.58	$-0.48	$-0.38	$-0.37	$0.10	$-0.31	$-0.28	$-0.23	$-0.24
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.89%	1.12%	1.01%	0.92%	1.07%	0.90%	1.02%	-3.30%	1.24%	1.04%	1.41%	0.85%

According to undefined Wall Street analysts, Recursion Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RXRX previous annual EPS of $NaN (undefined).

Recursion Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.52	$70.00	13361.54%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
AFMD	Affimed	$1.51	$7.50	396.69%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
CNSP	CNS Pharmaceuticals	$0.11	$0.50	354.55%
SANA	Sana Bio	$1.91	$8.00	318.85%	Buy
RLAY	Relay Therapeutics	$4.50	$18.00	300.00%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
IMMX	Immix Biopharma	$2.29	$7.00	205.68%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
ABSI	Absci	$3.33	$6.00	80.18%	Buy
RXRX	Recursion Pharmaceuticals	$7.12	$9.67	35.81%	Hold

RXRX Forecast FAQ

Is Recursion Pharmaceuticals a good buy?

No, according to 5 Wall Street analysts, Recursion Pharmaceuticals (RXRX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 20.00% of RXRX's total ratings.

What is RXRX's price target?

Recursion Pharmaceuticals (RXRX) average price target is $9.67 with a range of $6 to $12, implying a 60.36% from its last price of $6.03. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Recursion Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for RXRX stock, the company can go up by 60.36% (from the last price of $6.03 to the average price target of $9.67), up by 99.00% based on the highest stock price target, and down by -0.50% based on the lowest stock price target.

Can Recursion Pharmaceuticals stock reach $9?

RXRX's average twelve months analyst stock price target of $9.67 supports the claim that Recursion Pharmaceuticals can reach $9 in the near future.

What are Recursion Pharmaceuticals's analysts' financial forecasts?

Recursion Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $60.71M (high $91.36M, low $32.69M), average EBITDA is $-60.708M (high $-32.686M, low $-91.357M), average net income is $-533M (high $-213M, low $-882M), average SG&A $349.53M (high $525.99M, low $188.19M), and average EPS is $-1.885 (high $-0.754, low $-3.122). RXRX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $75M (high $112.86M, low $40.38M), average EBITDA is $-75M (high $-40.381M, low $-113M), average net income is $-356M (high $-142M, low $-590M), average SG&A $431.81M (high $649.81M, low $232.49M), and average EPS is $-1.26 (high $-0.504, low $-2.087).

Did the RXRX's actual financial results beat the analysts' financial forecasts?

Based on Recursion Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $44.58M, which missed the average analysts forecast of $55.81M by -20.13%. Apple's EBITDA was $-350M, beating the average prediction of $-55.807M by 527.26%. The company's net income was $-328M, missing the average estimation of $-440M by -25.47%. Apple's SG&A was $110.82M, missing the average forecast of $321.31M by -65.51%. Lastly, the company's EPS was $-1.58, beating the average prediction of $-1.558 by 1.43%. In terms of the last quarterly report (Dec 2023), Recursion Pharmaceuticals's revenue was $10.89M, missing the average analysts' forecast of $19.9M by -45.26%. The company's EBITDA was $-98.93M, beating the average prediction of $-19.895M by 397.26%. Recursion Pharmaceuticals's net income was $-92.996M, missing the average estimation of $-127M by -26.66%. The company's SG&A was $30.46M, missing the average forecast of $114.55M by -73.41%. Lastly, the company's EPS was $-0.4, missing the average prediction of $-0.449 by -10.86%